Artificial Intelligence: Now a Priority for Labs

By Robert Michel | From the Volume XXX, Number 17 – December 4, 2023 Issue

CEO SUMMARY: It’s time to recognize the field of artificial Intelligence as the next major source of disruption. Not only will clinical laboratories, anatomic pathology groups, and diagnostics companies be disrupted by AI-powered technologies, but experts predict that almost eve…

Read More

---

Digital Pathology Rollout Was ‘Big Bang’ at University of Louisville

By Scott Wallask | From the Volume XXX, No. 11 – July 31, 2023 Issue

CEO SUMMARY: It took less than one year to achieve full implementation of whole slide imaging and digital pathology at the University of Louisville’s Department of Pathology. One decision was to s…

Read More

---

Digital Pathology Business Plan for Both Clinical and ROI Success

By Kristin Althea O’Connor | From the Volume XXX, No. 9 – June 19, 2023 Issue

CEO SUMMARY: More pathology groups are ready to consider adopting whole-slide imaging and digital pathology. The decision to proceed should only be made after identifying the clinica…

Read More

---

Artificial Intelligence ‘Invades’ Pathology, Billing

By R. Lewis Dark | From the Volume XXIX, No. 3 – February 22, 2022 Issue

Predictions about the potential of artificial intelligence (AI) to transform nearly every area of healthcare are about to become reality. For the profession of laboratory medicine, AI is making speedy inroads into two areas. The first is anato…

Read More

---

First Digital Path AI Tool Cleared for Market by FDA

By Robert Michel | From the Volume XXVIII, No. 13 – September 27, 2021 Issue

CEO SUMMARY: In a first for the anatomic pathology profession, the Food and Drug Administration (FDA) has cleared for market a digital pathology image analysis product intended to aid pathologists in the diagnosis of prostate cancer. Developed by New York City-based Paige, the Paige…

Read More

---

Proscia Lands Major Deals as Digital Pathology Demand Grows

By Robert Michel | From the Volume XXVIII, No. 2 – February 8, 2021 Issue

EVEN AS THE WORLDWIDE COVID-19 PANDEMIC DERAILED SOME INDUSTRIES, it gave a major boost to digital pathology. That has meant an expanding market for Proscia, a seven-year-old provider of digital and computational pathology solutions. Established in 2014, Proscia recently won …

Read More

---

Expert Sees Pros, Cons In DP and WSI Systems

By Joseph Burns | From the Volume XXVI No. 13 – September 23, 2019 Issue

CEO SUMMARY: Now that the FDA has cleared two digital pathology systems for use in primary diagnosis, a growing number of pathology groups are taking up the question of whether and when they should adopt and use a digital pathology system and whole slide imaging. One pathologist with hand…

Read More

---

FDA Clears Aperio’s Digital Pathology System

By Joseph Burns | From the Volume XXVI No. 10 – July 22, 2019 Issue

CEO SUMMARY: In May, the FDA announced clearance for Leica Biosystems to market its Aperio AT2 DX System for clinical diagnosis in the United States. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to pathologists reviewing and interpreting digital images of sur…

Read More

---

GE Healthcare Sells Omnyx to Inspirata

By Joseph Burns | From the Volume XXV No. 3 – February 12, 2018 Issue

CEO SUMMARY: Now that the FDA has cleared a digital pathology for use in primary diagnosis, interest in DP is building. Inspirata purchased Omnyx and its assets because the Omnyx Dynamyx digital pathology software has strong features that could be integrated into Inspirata’s digital pat…

Read More

---

TOP 10 LAB STORIES OF 2017

By Robert Michel | From the Volume XXIV No. 17 – December 11, 2017 Issue

1. CMS Sticks by Decision to Deeply Cut Medicare Part B Lab Test Fees SHORT OF A MIRACLE, the clinical laboratory industry is less than three weeks from the single most financially-disruptive event of the past 30 years. On Jan. 1, the federal Centers for Medicare and Medicaid Service…

Read More

---